| Primary |
| Chronic Lymphocytic Leukaemia |
26.2% |
| Bone Marrow Conditioning Regimen |
9.6% |
| Prophylaxis Against Graft Versus Host Disease |
9.3% |
| Stem Cell Transplant |
9.2% |
| Acute Myeloid Leukaemia |
6.3% |
| Prophylaxis |
5.5% |
| Non-hodgkin's Lymphoma |
4.4% |
| B-cell Lymphoma |
4.3% |
| Antifungal Prophylaxis |
3.4% |
| Mantle Cell Lymphoma |
3.3% |
| Infection Prophylaxis |
3.0% |
| Antiviral Prophylaxis |
2.6% |
| Drug Use For Unknown Indication |
2.3% |
| Cord Blood Transplant Therapy |
1.9% |
| Metastatic Malignant Melanoma |
1.8% |
| Immunosuppression |
1.5% |
| Bone Marrow Transplant |
1.4% |
| B-cell Small Lymphocytic Lymphoma |
1.4% |
| Chemotherapy |
1.4% |
| Malignant Melanoma |
1.2% |
|
| Thrombocytopenia |
9.8% |
| Vomiting |
8.2% |
| Pyrexia |
7.7% |
| Neutropenia |
6.0% |
| Sepsis |
6.0% |
| Blood Stem Cell Harvest Failure |
5.7% |
| Premature Menopause |
5.7% |
| Myelodysplastic Syndrome |
5.5% |
| Renal Failure |
4.9% |
| Progressive Multifocal Leukoencephalopathy |
4.6% |
| Respiratory Failure |
4.6% |
| Acute Myeloid Leukaemia |
4.1% |
| Pancytopenia |
4.1% |
| Septic Shock |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Myeloid Leukaemia |
3.3% |
| Renal Failure Acute |
3.3% |
| Transplant Failure |
3.3% |
| Off Label Use |
2.7% |
| Pulmonary Oedema |
2.7% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
31.3% |
| Drug Use For Unknown Indication |
12.0% |
| Product Used For Unknown Indication |
7.0% |
| Prophylaxis |
5.4% |
| Stem Cell Transplant |
4.9% |
| B-cell Lymphoma |
4.7% |
| Acute Myeloid Leukaemia |
4.5% |
| Non-hodgkin's Lymphoma |
4.5% |
| Mantle Cell Lymphoma |
3.6% |
| Bone Marrow Conditioning Regimen |
3.4% |
| Prophylaxis Against Graft Versus Host Disease |
3.2% |
| Lymphoma |
3.1% |
| Premedication |
2.7% |
| Multiple Myeloma |
1.9% |
| Infection Prophylaxis |
1.7% |
| Graft Versus Host Disease |
1.4% |
| Bone Marrow Transplant |
1.2% |
| Acute Lymphocytic Leukaemia |
1.2% |
| Immunosuppression |
1.1% |
| Ewing's Sarcoma |
1.1% |
|
| Febrile Neutropenia |
13.1% |
| Myelodysplastic Syndrome |
8.3% |
| Progressive Multifocal Leukoencephalopathy |
6.7% |
| Sepsis |
6.6% |
| Neutropenia |
6.4% |
| Pneumonia |
6.2% |
| Vomiting |
6.0% |
| Pyrexia |
5.7% |
| Thrombocytopenia |
4.9% |
| White Blood Cell Count Decreased |
4.1% |
| Blood Stem Cell Harvest Failure |
3.9% |
| Death |
3.9% |
| Acute Myeloid Leukaemia |
3.6% |
| Septic Shock |
3.6% |
| Graft Versus Host Disease |
3.2% |
| Pancytopenia |
3.2% |
| Respiratory Failure |
3.1% |
| Thrombotic Microangiopathy |
2.7% |
| Cytomegalovirus Infection |
2.4% |
| Premature Menopause |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
14.1% |
| Bone Marrow Conditioning Regimen |
13.3% |
| Prophylaxis Against Graft Versus Host Disease |
13.3% |
| Stem Cell Transplant |
9.2% |
| Infection Prophylaxis |
9.1% |
| Prophylaxis |
9.0% |
| Chronic Lymphocytic Leukaemia |
3.9% |
| Premedication |
3.8% |
| Drug Use For Unknown Indication |
3.5% |
| Antifungal Prophylaxis |
2.9% |
| Cord Blood Transplant Therapy |
2.7% |
| Acute Myeloid Leukaemia |
2.4% |
| Antibiotic Prophylaxis |
1.9% |
| Antiviral Prophylaxis |
1.9% |
| Non-hodgkin's Lymphoma |
1.9% |
| B-cell Lymphoma |
1.8% |
| Graft Versus Host Disease |
1.5% |
| Aplastic Anaemia |
1.3% |
| Bone Marrow Transplant |
1.3% |
| Prophylaxis Of Nausea And Vomiting |
1.2% |
|
| Acute Graft Versus Host Disease |
9.5% |
| Progressive Multifocal Leukoencephalopathy |
8.9% |
| Stomatitis |
7.9% |
| Thrombotic Microangiopathy |
7.7% |
| Vomiting |
7.4% |
| Pyrexia |
7.2% |
| Venoocclusive Liver Disease |
6.3% |
| Stem Cell Transplant |
5.0% |
| Drug Ineffective |
4.7% |
| Sepsis |
4.7% |
| White Blood Cell Count Decreased |
4.3% |
| Death |
3.4% |
| Graft Versus Host Disease |
3.2% |
| Acute Graft Versus Host Disease In Skin |
3.1% |
| Febrile Neutropenia |
3.1% |
| Thrombocytopenia |
3.1% |
| Septic Shock |
2.8% |
| Neutropenia |
2.7% |
| Acute Myeloid Leukaemia |
2.6% |
| Pneumonia |
2.6% |
|
| Interacting |
| Lymphoma |
50.0% |
| Chronic Lymphocytic Leukaemia |
12.0% |
| Epilepsy |
10.0% |
| Non-hodgkin's Lymphoma |
10.0% |
| Nausea |
8.0% |
| Prophylaxis |
4.0% |
| Anticoagulant Therapy |
2.0% |
| Deep Vein Thrombosis |
2.0% |
| Pneumonitis |
2.0% |
|
| Nausea |
62.5% |
| Anticoagulation Drug Level Above Therapeutic |
12.5% |
| Leukopenia |
12.5% |
| Sepsis |
12.5% |
|
